European News

    • Locked
    Daiichi Sankyo Initiates Pivotal Phase 2 Study of DS-8201 in Patients with HER2-Positive Metastatic Breast Cancer
    • Locked
    FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo’s DS-8201 for HER2-Positive Metastatic Breast Cancer
    • Locked
    Bristol-Myers Squibb and Daiichi Sankyo Announce Research Collaboration to Evaluate Opdivo® (nivolumab) and DS-8201 in HER2-Expressing Breast and Bladder Cancers
  • Daiichi Sankyo Enters Worldwide Licensing Agreement with Boston Pharmaceuticals for a Highly Selective RET Inhibitor for Solid Tumors
    • Locked
    New sub-analysis data highlights the benefit of LIXIANA®▼ (edoxaban) over warfarin in NVAF patients according to more comprehensive stroke risk scoring
  • Zymeworks and Daiichi Sankyo Announce Successful Achievement of a Research Milestone in Bispecific Antibody Collaboration
    • Locked
    CHMP Issues a Positive Opinion for Daiichi Sankyo’s Once-Daily LIXIANA® (edoxaban) in Patients with Atrial Fibrillation Undergoing Cardioversion
  • Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center Announce Cancer Research Collaboration
    • Locked
    Daiichi Sankyo Announces New Analyses of Once-Daily LIXIANA® (edoxaban) to be Presented at the ISTH 2017 Congress
    • Locked
    New Precision Medicine Data on DS-8201 in HER2-Expressing Breast Cancer Revealed at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
back to top

User login

Enter your username and password here in order to log in on the website